First Trust NYSE Arca Biotechnology Index Fund

Fund Name:
First Trust NYSE Arca Biotechnology Index Fund
First Trust
Total Net Assets:
Related Index:
NYSE Arca Biotechnology Index
ETF Category: 
Expense Ratio: 
Net Asset Value: 
Recent NAV Premium: 
NAV Symbol: 
Number of Holdings: 
Annualized Yield: 
Annualized Distribution: 
Stock Weight Amount
Regeneron Pharmaceuticals, 4.83% $70,542,361
Gilead Sciences, 4.55% $66,567,419
Qiagen N.V. 4.35% $63,658,536
Biogen 4.10% $59,971,037
Seattle Genetics, 4.02% $58,789,282
List of all 32 stocks held by FBT »
Quotes delayed 20 minutes

Buy (3.23 out of 4)
70th percentile
(ranked higher than approx. 70% of all etfs covered)
Based on data provided by Zacks Investment Research via
ETF Assets
FVD   $7,870,147,687
FDN   $6,681,393,534
LMBS   $5,013,340,824
FTSM   $4,550,974,298
FPE   $4,251,321,355
List of all 142 others »
Shares Short 21,049
Chg. from Last Month -3,968
Shares Outstanding 11,150,002
% of Shares Short 0.19%
Days to Cover 0.1
Based on third party short interest data.

FBT | First Trust NYSE Arca Biotechnology Index Fund | ETF Channel |

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.